Encysive Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel synthetic small molecule compounds for the treatment of various cardiovascular, vascular, and related inflammatory diseases. It offers Argatroban, a synthetic direct thrombin inhibitor, for the treatment of heparin-induced thrombocytopenia in the United States and Canada; and Thelin (sitaxsentan sodium), an endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension in the European Union and Australia. It also has three additional compounds in clinical development, including TBC3711, second-generation endothelin receptor antagonist; TBC4746, an oral VLA-4 antagonist; and bimosiamose, a selectin antagonist. In addition, the company provides other research and development programs for various cardiovascular and inflammatory diseases. Encysive Pharmaceuticals has collaboration and licensing agreements with Mitsubishi Pharma Corporation; GlaxoSmithKline plc; Schering Corporation; Schering-Plough, Ltd.; and Revotar Biopharmaceuticals, AG. The company was founded in 1989. It was formerly known as Texas Biotechnology Corporation and changed its name to Encysive Pharmaceuticals, Inc. in 2003. Encysive Pharmaceuticals is headquartered in Houston, Texas.